Recent R&D Highlights
- 5 Downloads
Esperion Inspires Industry
In November 2003, Esperion Therapeutics Inc. stunned the pharmaceutical industry by providing evidence that its ApoA-I Milano/phospholipid complex ETC 216 rapidly reversed atherosclerosis. Results from a phase II trial showed that ETC 216 reduced the size of plaque in coronary arteries and reversed atherosclerosis within 6 weeks. “These results demonstrate for the first time that it is possible to rapidly regress the major underlying cause of heart attack,” said company president and CEO Roger Newton.
Observational studies have consistently shown that plasma levels of HDL-cholesterol and its major protein apolipoprotein A-I (apoA-I) are inversely correlated with coronary heart disease risk.1Consequently, HDL-cholesterol and apoA-I have become the focus of R&D programs developing new therapies for atherosclerosis. Until recently, the search for small molecules that can upregulate the genetic expression of apolipoprotein A-I (apoA-I) had proved elusive....